Verastem makes its stand as a RevMed competitor in pancreatic cancer
Verastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massachusetts ...
read at Endpoints ↗Neutral
October 14, 2026 11:52 AM EDTUpdated 12:18 PM PeopleR&D Verastem makes its stand as a RevMed competitor in pancreatic cancer Lei Lei Wu News Reporter Verastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that